Nanoparticle device to be tested in cancer patients

A Paris-based life science company, Nanobiotix SA, has received clearance to start a Phase 1 safety study of a new nanoproduct in patients with soft-tissue sarcoma. The product has been classified as a device in Europe, but as a drug in the US.